Susquehanna International Group
BBC icon

Susquehanna International Group’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Susquehanna International Group’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Buy
52,053
+30,091
+137% +$1.23M ﹤0.01% 5993
2025
Q4 		$847K Sell
21,962
-12,609
-36% -$428K ﹤0.01% 7555
2025
Q3 		$944K Buy
34,571
+23,458
+211% +$535K ﹤0.01% 7494
2025
Q2 		$215K Buy
+11,113
New +$202K ﹤0.01% 11070
2025
Q1 		– Sell
-43,735
Closed -$1.05M – 12465
2024
Q4 		$1.05M Sell
43,735
-2,374
-5% -$65.5K ﹤0.01% 6834
2024
Q3 		$1.29M Buy
46,109
+12,565
+37% +$347K ﹤0.01% 6246
2024
Q2 		$847K Buy
33,544
+21,177
+171% +$565K ﹤0.01% 6979
2024
Q1 		$360K Sell
12,367
-35,485
-74% -$973K ﹤0.01% 9279
2023
Q4 		$1.17M Buy
+47,852
New +$944K ﹤0.01% 6597
2023
Q3 		– Sell
-36,777
Closed -$881K – 12002
2023
Q2 		$881K Buy
36,777
+26,130
+245% +$629K ﹤0.01% 6993
2023
Q1 		$233K Sell
10,647
-25,137
-70% -$633K ﹤0.01% 10261
2022
Q4 		$894K Buy
35,784
+15,501
+76% +$386K ﹤0.01% 6424
2022
Q3 		$499K Buy
+20,283
New +$517K ﹤0.01% 8493
2022
Q1 		– Sell
-9,830
Closed -$379K – 12963
2021
Q4 		$379K Buy
9,830
+1,562
+19% +$66.6K ﹤0.01% 9917
2021
Q3 		$378K Sell
8,268
-5,318
-39% -$249K ﹤0.01% 10064
2021
Q2 		$678K Sell
13,586
-12,103
-47% -$592K ﹤0.01% 8823
2021
Q1 		$1.32M Buy
25,689
+7,933
+45% +$434K ﹤0.01% 6992
2020
Q4 		$881K Sell
17,756
-31,084
-64% -$1.4M ﹤0.01% 7013
2020
Q3 		$1.9M Buy
48,840
+29,457
+152% +$1.2M ﹤0.01% 4721
2020
Q2 		$837K Buy
19,383
+6,099
+46% +$233K ﹤0.01% 6286
2020
Q1 		$389K Buy
13,284
+703
+6% +$24.2K ﹤0.01% 7465
2019
Q4 		$479K Buy
+12,581
New +$374K ﹤0.01% 7069
2019
Q2 		– Sell
-18,990
Closed -$541K – 10200
2019
Q1 		$541K Sell
18,990
-8,568
-31% -$224K ﹤0.01% 6116
2018
Q4 		$640K Buy
27,558
+21,747
+374% +$593K ﹤0.01% 5547
2018
Q3 		$201K Buy
+5,811
New +$196K ﹤0.01% 8208
2016
Q4 		– Sell
-25,119
Closed -$569K – 9552
2016
Q3 		$569K Buy
25,119
+7,300
+41% +$150K ﹤0.01% 5838
2016
Q2 		$321K Sell
17,819
-6,393
-26% -$125K ﹤0.01% 6841
2016
Q1 		$463K Sell
24,212
-8,255
-25% -$160K ﹤0.01% 6540
2015
Q4 		$943K Buy
32,467
+9,523
+42% +$275K ﹤0.01% 5529
2015
Q3 		$606K Buy
+22,944
New +$776K ﹤0.01% 6736

Other funds holding BBC

KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
MCM
Militia Capital Management Austin, Texas $454M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
APW
Aurora Private Wealth Rockaway, New Jersey $158M AUM
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
GAA
Global Assets Advisory Orlando, Florida $458M AUM 29.73% 1-Year Est. Return

Susquehanna International Group's BBC Position: Q1 2026 in Review

Susquehanna International Group increased its Virtus Biotech Clinical Trials ETF (BBC) stake by 137% in Q1 2026, buying an estimated $1.23M and bringing the position to 52,053 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5993.

Susquehanna International Group first reported a position in BBC in Q3 2015 and has held it in 30 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

  • Susquehanna International Group held 52,053 shares of Virtus Biotech Clinical Trials ETF worth $2.17M as of Q1 2026.
  • Susquehanna International Group bought 30,091 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $1.23M.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5993 holding.
  • Susquehanna International Group first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2015 and has held it in 30 quarters since.
  • 20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.